$CYDY News

CytoDyn Inc. (CYDY) Discusses Corporate and Clinical Update With Focus on Leronlimab Development and Recent Financing Transcript

CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer

CytoDyn to Host Investor Webcast

CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026

CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study

CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026

CytoDyn to Present at the AACR Annual Meeting 2026

CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer

CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab

Creatv Bio's LifeTracDx® Blood Test Utilized as Exploratory Biomarker in CytoDyn's Phase 2 Study in Patients with Relapsed/Refractory Metastatic Colorectal Cancer

CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference

CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer

December 2025 Letter to Shareholders

CytoDyn to Showcase PD-L1 Upregulation and Improved Survival in Metastatic Triple Negative Breast Cancer at the San Antonio Breast Cancer Symposium

CytoDyn Announces Resolution of Class Action Lawsuit

CytoDyn to Present Prolonged Survival Data on Leronlimab in Metastatic Triple-Negative Breast Cancer at the San Antonio Breast Cancer Symposium

CytoDyn Secures $30 Million Commitment from Yorkville Advisors

CytoDyn to Present at the LD Micro Main Event XIX Investor Conference

September 2025 Letter to Shareholders

CytoDyn to present poster at AACR conference on mTNBC